Market Intelligence for ADC Development, Neuronal Transport Research, and High-Purity Reagents for Oncology & Neurodegeneration Programs.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CLSTN1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLSTN1 ECD-Fc Fusion Protein / Mutant Protein. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View CLSTN1 Products |
| Gene Delivery | CLSTN1 Promise-ORF / Lentivirus. Full-length ORF for stable cell line generation. Preserves Type I membrane topology; internalization assay ready. | View CLSTN1 Products |
| Benchmark Ab | Anti-CLSTN1 Recombinant Antibody. Positive control for binding, imaging, and internalization assays. | View CLSTN1 Products |
| Validator | CLSTN1 siRNA Set. For knockdown verification and specificity controls. | View CLSTN1 Products |
| Related Target: APP | Amyloid Precursor Protein. Shared vesicular trafficking pathway; functional interactor in axonal transport and Alzheimer's pathogenesis. | View APP Products |
| Related Target: CLSTN2 | Calsyntenin-2. Paralog for subfamily off-target counter-screening and selectivity validation. | View CLSTN2 Products |
| Related Target: CLSTN3 | Calsyntenin-3. Third family member for comprehensive off-target assessment. | View CLSTN3 Products |
| Related Target: BACE1 | Beta-secretase 1. Cleavage enzyme associated with CLSTN1 processing in amyloidogenic pathway. | View BACE1 Products |
Critical Assay Challenges and TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation for preclinical translation | Human/Mouse/Cyno ortholog proteins available with >95% purity; Sequence identity verified by mass spec. |
| Calsyntenin subfamily counter screening (CLSTN1 vs CLSTN2/3) | Homolog panel proteins strictly verified by mass spec; Theoretical MW confirmed. |
| ADC internalization efficiency confirmation | ECD-Fc constructs (HEK293) preserve native conformation and glycosylation; Lentivirus systems for surface expression validation. |
| Maintaining physiological conformation for protein-protein interaction assays | HEK293 expressed ECD proteins (native glycosylation) with >95% purity, suitable for SPR/BLI. |
| Lack of proper controls (siRNA, antibody) | Sequence-verified siRNA and recombinant Benchmark Antibodies included for specificity checks and assay standardization. |
| False positives in neuronal models | Verified siRNA and reference antibodies to confirm target-specific signals. |
Live CLSTN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest ADC Internalization Research and Resistance Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The CLSTN1 therapeutic landscape is bifurcated between oncology ADC development and neurodegenerative disease research. In oncology, CLSTN1 emerges as a novel target for solid tumor ADCs, leveraging its cell-surface expression in specific cancer indications (gastric, lung) and favorable internalization kinetics. As first-generation ADCs targeting CLSTN1 enter preclinical validation, the critical differentiation point lies in internalization efficiency versus off-target binding to CLSTN2/CLSTN3. The next wave of R&D focuses on epitope mapping near the membrane-proximal region to optimize therapeutic windows.
Simultaneously, the Alzheimer's disease sector continues investigating CLSTN1's role in APP processing and axonal transport mechanisms. CLSTN1 (UniProt O94985) is a type I membrane protein containing two cadherin domains that mediate cell adhesion and vesicular trafficking. Key mutations (e.g., dbSNP:rs7550295, rs17853245, rs17853244) have been cataloged and may influence protein function. As first-generation anti-amyloid therapies reach the clinic, the next wave of R&D targets the intracellular transport mechanisms governed by CLSTN1 to prevent amyloidogenic processing upstream. Drug modalities under exploration include monoclonal antibodies, small molecule PPI inhibitors, and gene therapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Emerging Biotechs, Oncology Focused Pharma | Solid Tumors (Gastric, Lung) | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| Diagnostic Imaging | Radiopharma Developers | Tumor Staging | Cell surface binding validation (Need Lentivirus-expressed full-length protein) |
| Monoclonal Antibodies | Academic/Biotech Consortiums | Alzheimer's Disease | Binding affinity (Need high-purity ECD-Fc for SPR) |
| Small Molecules | Early-stage Biotechs | Neurodegeneration | PPI Inhibition Assay (Need CLSTN1/APP proteins) |
| Gene Therapy (AAV/siRNA) | CNS-focused Pharma | Cognitive Impairment | Knockdown validation (Need verified siRNA/Lentivirus) |
| Neurobiology Research | Academic Institutions | Alzheimer's Disease | Protein-Protein Interaction assays (Need WT vs Mutant proteins) |